The transaction is valued at ₹797 crore, subject to closing adjustments. As per the terms of the agreement, 50% of the sale consideration will be paid on the Closing Date, as defined in the BTA, while the remaining amount will be payable within 150 days from the Closing Date.
Also Read: Mankind Pharma aims to be debt-free by FY28: Managing Director Rajeev Juneja
The completion of the acquisition is contingent upon preconditions, closing actions, and other terms and conditions outlined in the agreement. Mankind Pharma noted that detailed disclosures were already provided in its earlier filing dated July 31, 2025.
First Quarter Results
Mankind Pharma reported an 18.1% year-on-year (YoY) decline in net profit at ₹444.6 crore for the first quarter, down from ₹543 crore in Q1FY25. However, revenue from operations surged 24.5% to ₹3,570 crore against ₹2,868 crore year-on-year.
At the operating level, EBITDA increased 26% to ₹847.6 crore in the first quarter of this fiscal year over ₹672.6 crore in the prior-year period. EBITDA margin improved slightly to 23.7% from 23.4%.
Also Read: Mankind Pharma eyes 26% FY26 growth as chronic therapies, OTC drive momentum
The company reported a 20.1% YoY fall in diluted earnings per share (EPS) to ₹10.6 for Q1FY26. Domestic revenue rose 18.9% to ₹3,101 crore, while export revenue surged 81.1% to ₹469 crore, aided by the consolidation of BSV and growth in the base business.
Mankind’s market share increased from 4.8% in March 2025 to 4.9% in June 2025, reflecting its continued outperformance relative to the Indian pharmaceutical market (IPM). For Q1FY26, secondary sales grew by 9.2% compared to IPM’s 8.6%.
Shares of Mankind Pharma Ltd ended at ₹2,464.00, down by ₹15.40, or 0.62%, on the BSE.
Also Read: Mankind Pharma shares extend gains over the last month after Jefferies raises target
